PB28, a cyclohexylpiperazine derivative, could be a potential strategy for Covid 19 because in a recent study it has been found more active than hydroxychloroquine without interaction with cardiac proteins. PB28 has been designed, developed, and biologically evaluated in the past decade in our research group. A possible mechanism to explain its surprising anti-COVID-19 activity is suggested.
Why PB28 Could Be a Covid 2019 Game Changer?
Nicola Antonio Colabufo
;Marcello Leopoldo;Savina Ferorelli;Carmen Abate;Marialessandra Contino;Maria Grazia Perrone;Mauro Niso;Roberto Perrone;Francesco Berardi
2020-01-01
Abstract
PB28, a cyclohexylpiperazine derivative, could be a potential strategy for Covid 19 because in a recent study it has been found more active than hydroxychloroquine without interaction with cardiac proteins. PB28 has been designed, developed, and biologically evaluated in the past decade in our research group. A possible mechanism to explain its surprising anti-COVID-19 activity is suggested.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
acsmedchemlett.0c00271.pdf
accesso aperto
Tipologia:
Documento in Versione Editoriale
Licenza:
Creative commons
Dimensione
817.42 kB
Formato
Adobe PDF
|
817.42 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
